Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study

被引：0
|
作者：
Cicardi, M. [1 ]
Shennak, M. [2 ]
Zaragoza-Urdaz, R. H. [3 ]
Wang, Y. [4 ]
Lu, P. [4 ]
机构：
[1] Univ Milan, Dept Biomed & Clin Sci, ASST Fatebenefratelli Sacco, Luigi Sacco, Milan, Italy
[2] Triumpharma, Amman, Jordan
[3] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA
[4] Shire, Lexington, MA USA
来源：
ALLERGY | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1428
引用
收藏
页码：722 / 722
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics (PK), Pharmacodynamics (PD), and Exposure-Response (E-R) Analyses Confirm the Effectiveness of Lanadelumab in Patients 2 to <12 Years Old With Hereditary Angioedema (HAE)
    Ahmed, Mariam
    Wang, Yi
    Yu, Ming
    Marier, Jean-Francois
    Bhattacharya, Indranil
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB130 - AB130
  • [22] Subgroup Analyses From the Phase 3 HELP Study of Lanadelumab for the Prevention of Hereditary Angioedema Attacks
    Banerji, Aleena
    Manning, Michael E.
    Martinez-Saguer, Inmaculada
    Schwartz, Lawrence B.
    Smith, Andrew M.
    Yang, William H.
    Lu, Peng
    Hao, James
    Zuraw, Bruce L.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB43 - AB43
  • [23] Population pharmacokinetics and pharmacodynamics of febuxostat in a Phase-II study of patients with gout
    Khosravan, R
    Wu, JT
    Joseph-Ridge, N
    Kukulka, MJ
    Vernillet, L
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09) : 1083 - 1083
  • [24] QUALITY OF LIFE OF HEREDITARY ANGIOEDEMA (HAE) PATIENTS WITH DEPRESSION OR ANXIETY RECEIVING LANADELUMAB
    Craig, T.
    Soteres, D.
    Anderson, J.
    Paes, K.
    Hao, J.
    Hashemi, L.
    Watt, M.
    Juethner, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S25 - S25
  • [25] Lanadelumab treatment patterns among patients with HAE-C1-INH: Interim analysis of the ENABLE study
    Recke, A.
    Spadaro, G.
    Greve, J.
    Zanichelli, A.
    Hartmann, K.
    Agmon-Levin, N.
    Lleonart, R.
    Andriotti, T.
    Fei, K.
    Yegin, A.
    Aygoren-Pursun, E.
    ALLERGY, 2023, 78 : 12 - 13
  • [26] Long-term prevention of attacks with lanadelumab across subgroups of patients with hereditary angioedema (HAE): final results from the HELP open-label extension study
    Maurer, M.
    Bernstein, J. A.
    Jacobs, J.
    Lumry, W. R.
    Ren, H.
    Soteres, D.
    Yu, M.
    Martinez-Saguer, I
    ALLERGY, 2021, 76 : 10 - 10
  • [27] Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients
    Ide, S.
    Motwani, M.
    Jensen, M. R.
    Wang, J.
    Huseinovic, N.
    Stiegler, P.
    Wang, X.
    Quadt, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Population pharmacokinetics and pharmacodynamics of febuxostat in a Phase-III study of patients with gout.
    Khosravan, R
    Wu, J
    Joseph-Ridge, N
    Vernillet, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P21 - P21
  • [29] Pharmacokinetics and pharmacodynamics of natalizumab in a phase 2 study of adolescent patients with Crohn's disease
    不详
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (04) : 538 - 538
  • [30] Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience
    Hahn, Janina
    Trainotti, Susanne
    Wigand, Marlene C.
    Schuler, Patrick J.
    Hoffmann, Thomas K.
    Greve, Jens
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 978 - 983
12345